Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RNA
stocks logo

RNA

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.61M
-21.34%
-0.956
+47.05%
1.61M
-31.27%
-1.024
+57.55%
1.61M
-45.96%
-1.104
+37.96%
Estimates Revision
The market is revising Downward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by -11.51% over the past three months. During the same period, the stock price has changed by 18.37%.
Revenue Estimates for FY2025
Revise Downward
down Image
-11.51%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.77%
In Past 3 Month
Stock Price
Go Up
up Image
+18.37%
In Past 3 Month
16 Analyst Rating
up Image0
Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 67.06 USD with a low forecast of 50.00 USD and a high forecast of 96.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 33.760
sliders
Low
50.00
Averages
67.06
High
96.00
up Image0
Current: 33.760
sliders
Low
50.00
Averages
67.06
High
96.00
Evercore ISI
Gavin Clark-Gartner
Outperform
maintain
$60 -> $70
2025-07-11
Reason
Evercore ISI
Gavin Clark-Gartner
Price Target
$60 -> $70
2025-07-11
maintain
Outperform
Reason
Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on Avidity Biosciences to $70 from $60 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Goldman Sachs
NULL
to
Buy
initiated
$55
2025-07-10
Reason
Goldman Sachs
Price Target
$55
2025-07-10
initiated
NULL
to
Buy
Reason
Goldman Sachs resumed coverage of Avidity Biosciences with a Buy rating and $55 price target. The firm expects clarity over the next 12-18 months on the company's regulatory outlook.
Bernstein
Outperform
initiated
$50
2025-06-24
Reason
Bernstein
Price Target
$50
2025-06-24
initiated
Outperform
Reason
Wolfe Research
Andy Chen
Outperform
initiated
$55
2025-06-18
Reason
Wolfe Research
Andy Chen
Price Target
$55
2025-06-18
initiated
Outperform
Reason
Wolfe Research
NULL -> Outperform
initiated
$55
2025-06-17
Reason
Wolfe Research
Price Target
$55
2025-06-17
initiated
NULL -> Outperform
Reason
Wolfe Research initiated coverage of Avidity Biosciences with an Outperform rating and $55 price target.
Barclays
Overweight
maintain
$57 -> $59
2025-06-10
Reason
Barclays
Price Target
$57 -> $59
2025-06-10
maintain
Overweight
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Avidity Biosciences Inc (RNA.O) is -8.10, compared to its 5-year average forward P/E of -7.89. For a more detailed relative valuation and DCF analysis to assess Avidity Biosciences Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.89
Current PE
-8.10
Overvalued PE
-3.47
Undervalued PE
-12.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.71
Current EV/EBITDA
-4.88
Overvalued EV/EBITDA
-1.04
Undervalued EV/EBITDA
-8.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
212.29
Current PS
621.57
Overvalued PS
392.51
Undervalued PS
32.07

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 360.31% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 360.31% over the last month.
Sold
Bought

RNA News & Events

Events Timeline

(ET)
2025-07-17
11:58:09
Avidity, Phathom mentioned as potential takeout targets at Needham
select
2025-06-09 (ET)
2025-06-09
15:18:19
Avidity data strengthens accelerated approval case, says H.C. Wainwright
select
2025-06-09
12:48:05
Avidity Biosciences price target raised to $54 from $48 at BofA
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-14Benzinga
Veritex Holdings, Sequans Communications, Canaan And Other Big Stocks Moving Higher On Monday

  • U.S. Stock Market Overview: U.S. stocks experienced a slight decline, with the Dow Jones index dropping about 0.1%, while Veritex Holdings saw a significant increase of 22.1% following its acquisition announcement by Huntington Bancshares for $1.9 billion.

  • Notable Stock Performances: Several stocks recorded substantial gains, including Sequans Communications (up 20%), Canaan Inc. (up 19%), and SharpLink Gaming (up 18.8%), largely driven by rising Bitcoin prices and positive company announcements.

Preview
6.5
07-12TipRanks
Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy’ Stocks

  • Trump's Trade Tariffs: President Trump has announced significant tariffs on Canadian and Brazilian imports, with potential increases for other trading partners if new agreements are not reached, causing market uncertainty but also prompting optimism from analysts regarding long-term investment strategies.

  • Stock Recommendations: Analysts from Raymond James highlight two stocks, Achieve Life Sciences and Avidity Biosciences, as having substantial growth potential due to their innovative approaches in nicotine addiction treatment and RNA therapeutics, respectively, with projected price increases of up to 762% and 107%.

Preview
6.0
07-11Benzinga
Goldman Sachs Reinstates Buy on Avidity Biosciences, Announces $55 Price Target

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Avidity Biosciences Inc (RNA) stock price today?

The current price of RNA is 33.76 USD — it has decreased -0.82 % in the last trading day.

arrow icon

What is Avidity Biosciences Inc (RNA)'s business?

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

arrow icon

What is the price predicton of RNA Stock?

Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 67.06 USD with a low forecast of 50.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Avidity Biosciences Inc (RNA)'s revenue for the last quarter?

Avidity Biosciences Inc revenue for the last quarter amounts to 1.57M USD, decreased -55.60 % YoY.

arrow icon

What is Avidity Biosciences Inc (RNA)'s earnings per share (EPS) for the last quarter?

Avidity Biosciences Inc. EPS for the last quarter amounts to -0.90 USD, increased 13.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Avidity Biosciences Inc (RNA)'s fundamentals?

The market is revising Downward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by -11.51% over the past three months. During the same period, the stock price has changed by 18.37%.
arrow icon

How many employees does Avidity Biosciences Inc (RNA). have?

Avidity Biosciences Inc (RNA) has 391 emplpoyees as of July 19 2025.

arrow icon

What is Avidity Biosciences Inc (RNA) market cap?

Today RNA has the market capitalization of 4.07B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free